Fortification of Preservation Solution With Nitroprusside Does Not Alter Lung Allograft Survival in Clinical Human Lung Transplantation Article

Full Text via DOI: 10.31486/toj.19.0027 PMID: 31528134 Web of Science: 000485162400010

Cited authors

  • Boys, Joshua A.; Bowdish, Michael E.; Subramanyan, Ram Kumar; Shemanski, Kimberly A.; Dhillon, Gundeep S.; Toda, Koichi; Perrillo, Johanna; Seoane, Leonardo; Bates, Michael J.; Parrino, P. Eugene; Kooperkamp, Hannah; Valentine, Vincent G.; Emory, W. Brooks; Ochsner, John L.; McFadden, P. Michael


  • Background: Nitric oxide improves gas exchange following primary lung allograft dysfunction. Nitroprusside, a potent nitric oxide donor, has reduced reperfusion injury and improved oxygenation in experimental lung transplantation.; Methods: We sought to study the effect on lung allograft outcomes of fortifying the preservation solution with nitroprusside. We conducted a single-center clinical study of 46 consecutive lung recipients between 1998 and 2000: 24 patients received donor organs preserved in modified Euro-Collins solution with prostaglandin E1 (PGE1) (control group), and 22 patients received organs preserved in modified Euro-Collins with PGE1 and nitroprusside (NP group). The primary endpoint was overall survival.; Results: Baseline characteristics were similar between the groups except for a significantly longer graft ischemic time in the NP group vs the control group (253.3 +/- 52 vs 225.3 +/- 41 minutes, respectively, P=0.04). No significant differences were found in partial pressure arterial oxygen to fraction inspired oxygen ratio at <= 48 hours, primary graft dysfunction, or bronchiolitis obliterans-free days. Overall survival at 1, 3, and 5 years was 89%, 73%, and 63% in the control group and 76%, 38%, and 23% in the NP group. Log-rank survival analysis showed that the NP group had a significantly increased risk of mortality (P=0.034) compared to the control group.; Conclusion: The addition of nitroprusside to the lung transplant perfusate in this clinical trial did not improve survival; however, a large randomized trial would likely reduce confounding ischemia times and increase the power of the study.

Publication date

  • 2019

Published in

International Standard Serial Number (ISSN)

  • 1524-5012

Start page

  • 235

End page

  • 240


  • 19


  • 3